Sanofi's newly approved intradermal quadrivalent Fluzone forgoes the shot

The FDA approved Sanofi's ($SNY) Fluzone Intradermal Quadrivalent in adults ages 18 through 64. This addition to the company's flu vaccine portfolio is well received after last year's 94% surge in vaccine sales upon adding the quadrivalent contender to the mix. For those afraid of getting shots, Fluzone Intradermal might be an easier option. While it is administered directly into the skin, the microneedle is one-tenth the size of the typical needles used for intramuscular injection of flu vaccines. Story

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…